Stem cells, melanoma and cancer stem cells: the good, the bad and the evil?
- PMID: 19088701
Stem cells, melanoma and cancer stem cells: the good, the bad and the evil?
Abstract
Most cancers contain morphologically heterogeneous populations of cells. While this observation may partly be explained by the coexistence of multiple genetic sub-clones arising through independent somatic mutations and/or as a result of differentiation processes in the tumor microenvironment, it also implies that the tumor may be formed from undifferentiated ''stem cell-like'' cells called ''cancer stem cells'' or ''cancer-initiating cells''. These cells are thought to constitute one or several rare subpopulations in a given tumor and would be strongly responsible for initiation of tumor development and growth as well as for metastasis and recurrence after cytoreductive therapy. However, while the concept of cancer stem cells has been first established for human myeloid leukemia in the 1960s, it has only much later been extended to other solid tumors such as breast or brain cancers and most recently to melanoma. Thus, it is presently unclear which role a sufficiently characterized population of melanoma stem cells plays in cancer promotion and progression. Here, we review the emerging melanoma stem cell model and discuss the biological and therapeutic implications of the model.
Similar articles
-
Mechanisms of Disease: cancer stem cells--targeting the evil twin.Nat Clin Pract Oncol. 2008 Jun;5(6):337-47. doi: 10.1038/ncponc1110. Epub 2008 Apr 22. Nat Clin Pract Oncol. 2008. PMID: 18431377 Review.
-
Targeting cancer stem cells for more effective therapies: Taking out cancer's locomotive engine.Biochem Pharmacol. 2009 Aug 15;78(4):326-34. doi: 10.1016/j.bcp.2009.03.020. Epub 2009 Apr 1. Biochem Pharmacol. 2009. PMID: 19539800
-
Cancer stem cell: target for anti-cancer therapy.FASEB J. 2007 Dec;21(14):3777-85. doi: 10.1096/fj.07-8560rev. Epub 2007 Jul 11. FASEB J. 2007. PMID: 17625071 Review.
-
Mathematical models of cancer stem cells.J Clin Oncol. 2008 Jun 10;26(17):2854-61. doi: 10.1200/JCO.2007.15.2421. J Clin Oncol. 2008. PMID: 18539964 Review.
-
Pathogenesis of metastatic disease: implications for current therapy and for the development of new therapeutic strategies.Cancer Treat Rep. 1986 Jan;70(1):183-99. Cancer Treat Rep. 1986. PMID: 3510734 Review.
Cited by
-
Drug-selected population in melanoma A2058 cells as melanoma stem-like cells retained angiogenic features - the potential roles of heparan-sulfate binding ANGPTL4 protein.Aging (Albany NY). 2020 Nov 10;12(22):22700-22718. doi: 10.18632/aging.103890. Epub 2020 Nov 10. Aging (Albany NY). 2020. PMID: 33196458 Free PMC article.
-
Mechanisms of Melanoma Progression and Treatment Resistance: Role of Cancer Stem-like Cells.Cancers (Basel). 2024 Jan 22;16(2):470. doi: 10.3390/cancers16020470. Cancers (Basel). 2024. PMID: 38275910 Free PMC article. Review.
-
Current and future trials of targeted therapies in cutaneous melanoma.Adv Exp Med Biol. 2013;779:223-55. doi: 10.1007/978-1-4614-6176-0_10. Adv Exp Med Biol. 2013. PMID: 23288642 Free PMC article. Review.
-
Cancer Stem Cells in Neuroblastoma: Expanding the Therapeutic Frontier.Front Mol Neurosci. 2019 May 27;12:131. doi: 10.3389/fnmol.2019.00131. eCollection 2019. Front Mol Neurosci. 2019. PMID: 31191243 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials